Soy consumption alters endogenous estrogen metabolism in postmenopausal women.
Isoflavones are soy phytoestrogens that have been suggested to be anticarcinogenic. Our previous study in premenopausal women suggested that the mechanisms by which isoflavones exert cancer-preventive effects may involve modulation of estrogen metabolism away from production of potentially carcinogenic metabolites [16alpha-(OH) estrone, 4-(OH) estrone, and 4-(OH) estradiol] (X. Xu et al., Cancer Epidemiol. Biomark. Prev., 7: 1101-1108, 1998). To further evaluate this hypothesis, a randomized, cross-over soy isoflavone feeding study was performed in 18 healthy postmenopausal women. The study consisted of three diet periods, each separated by a washout of approximately 3 weeks. Each diet period lasted for 93 days, during which subjects consumed their habitual diets supplemented with soy protein isolate providing 0.1 (control), 1, or 2 mg isoflavones/kg body weight/day (7.1 +/- 1.1, 65 +/- 11, or 132 +/- 22 mg/day). A 72-h urine sample was collected 3 days before the study (baseline) and days 91-93 of each diet period. Urine samples were analyzed for 10 phytoestrogens and 15 endogenous estrogens and their metabolites by a capillary gas chromatography-mass spectrometry method. Compared with the soy-free baseline and very low isoflavone control diet, consumption of 65 mg isoflavones increased the urinary 2/16alpha-(OH) estrone ratio, and consumption of 65 or 132 mg isoflavones decreased excretion of 4-(OH) estrone. When compared with baseline values, consumption of all three soy diets increased the ratio of 2/4-(OH) estrogens and decreased the ratio of genotoxic: total estrogens. These data suggest that both isoflavones and other soy constituents may exert cancer-preventive effects in postmenopausal women by altering estrogen metabolism away from genotoxic metabolites toward inactive metabolites.
Xu
X
X
Department of Food Science and Nutrition, University of Minnesota, St. Paul 55108, USA.
Duncan
A M
AM
Wangen
K E
KE
Kurzer
M S
MS
D000704:Analysis of Variance; D016588:Anticarcinogenic Agents / Q000627:therapeutic use* / Q000652:urine; D001943:Breast Neoplasms / Q000517:prevention & control*; D018592:Cross-Over Studies; D004967:Estrogens / Q000378:metabolism* / Q000652:urine; D004968:Estrogens, Non-Steroidal / Q000652:urine; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use* / Q000652:urine; D016018:Least-Squares Analysis; D008875:Middle Aged; D048789:Phytoestrogens; D028321:Plant Preparations; D017698:Postmenopause / Q000378:metabolism* / Q000652:urine; D030262:Soybean Proteins / Q000627:therapeutic use* / Q000652:urine
D016588:Anticarcinogenic Agents; D004967:Estrogens; D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D048789:Phytoestrogens; D028321:Plant Preparations; D030262:Soybean Proteins